Hope In A Pill
A crop of small-molecule drugs in development could double the treatment options for people with multiple sclerosis in coming years
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
April 6, 2009 Cover
Volume 87, Issue 14
A crop of small-molecule drugs in development could double the treatment options for people with multiple sclerosis in coming years
Credit:
A crop of small-molecule drugs in development could double the treatment options for people with multiple sclerosis in coming years
Epigenetics, the molecular framework that controls genes’ expression, takes its cues from both nature and nurture
Rival bills in Congress differ in how long innovators can enjoy market exclusivity
Epigenetic modifications alter chromatin landscape, turn genes on and off
Too much defense and not enough offense at drug industry event
Diplomats begin working out new global treaty to curb greenhouse gas emissions
The founding generation of epigenetics-based drugs combine promise and peril